| Kevin D Delduca, MD | |
|
2500 S Woodworth Loop, Palmer, AK 99645-8984 | |
| (907) 861-6000 | |
| Not Available |
| Full Name | Kevin D Delduca |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 34 Years |
| Location | 2500 S Woodworth Loop, Palmer, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023146149 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 3482 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mat-su Regional Medical Center | Palmer, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Matsu Emergency Medicine Physicians Corp | 1557251022 | 15 |
News Archive
Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.
Evidence is growing from animal and human studies that genistein, a potent chemical found in soy, protects against development of breast cancer - but only if consumed during puberty, says a Georgetown University Medical Center researcher in the British Journal of Cancer published online today.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options.
› Verified 2 days ago
| Entity Name | Matsu Emergency Medicine Physicians Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073548129 PECOS PAC ID: 1557251022 Enrollment ID: O20040318000130 |
News Archive
Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.
Evidence is growing from animal and human studies that genistein, a potent chemical found in soy, protects against development of breast cancer - but only if consumed during puberty, says a Georgetown University Medical Center researcher in the British Journal of Cancer published online today.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options.
› Verified 2 days ago
| Entity Name | Juneau Emergency Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912393356 PECOS PAC ID: 2466745351 Enrollment ID: O20160729002119 |
News Archive
Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.
Evidence is growing from animal and human studies that genistein, a potent chemical found in soy, protects against development of breast cancer - but only if consumed during puberty, says a Georgetown University Medical Center researcher in the British Journal of Cancer published online today.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin D Delduca, MD Po Box 718, Palmer, AK 99645-0718 Ph: (907) 746-7511 | Kevin D Delduca, MD 2500 S Woodworth Loop, Palmer, AK 99645-8984 Ph: (907) 861-6000 |
News Archive
Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.
Evidence is growing from animal and human studies that genistein, a potent chemical found in soy, protects against development of breast cancer - but only if consumed during puberty, says a Georgetown University Medical Center researcher in the British Journal of Cancer published online today.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.
In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options.
› Verified 2 days ago
Meghan L Lindstrom, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Thomas W Quimby, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6620 | |
Michael Robert Alter, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Thomas John Check, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
David Anderson Grove Jr., MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Thomas Edward Leigh, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 |